• Events
    • Future Meetings
    • Digital Events
    • EURETINA 2022 Hamburg
      • Browse Programme
      • Registration Information
      • Hotel Bookings
    • EURETINA 2021 Virtual
      • 2021 Virtual Sessions On-Demand (Members Only)
      • Programme
      • Satellite Symposia
      • Sponsors
  • Free Resources
    • Webinars
    • Podcasts
    • 2021 Virtual Session Abstracts
    • EURETINA Guidelines
    • EURETINA Brief
    • IME ePlatform
  • Membership
  • About
    • EURETINA Board
    • Subspecialty Sections
    • Bye-laws
  • Opportunities
    • Mentorship Programme 2022/23
    • RMCR grant programme
    • Observership Grant Programme
    • Women in Retina
    • YOURS
    • CME Credits
  • Member Login
Menu
  • Events
    • Future Meetings
    • Digital Events
    • EURETINA 2022 Hamburg
      • Browse Programme
      • Registration Information
      • Hotel Bookings
    • EURETINA 2021 Virtual
      • 2021 Virtual Sessions On-Demand (Members Only)
      • Programme
      • Satellite Symposia
      • Sponsors
  • Free Resources
    • Webinars
    • Podcasts
    • 2021 Virtual Session Abstracts
    • EURETINA Guidelines
    • EURETINA Brief
    • IME ePlatform
  • Membership
  • About
    • EURETINA Board
    • Subspecialty Sections
    • Bye-laws
  • Opportunities
    • Mentorship Programme 2022/23
    • RMCR grant programme
    • Observership Grant Programme
    • Women in Retina
    • YOURS
    • CME Credits
  • Member Login
  • February 28, 2020
  • Author: EURETINA Brief

Reports have identified concerns for medical complications from Novartis’ brolucizumab (Beovu) product for wet AMD.

Reports in the New York Times and Eyewire News have indicated that Novartis has launched an internal review of information that raises serious safety concerns on the use of brolucizumab (Beovu), for AMD.  In addition, according to the American Society of Retina Specialists (ASRS), there have been 14 cases of retinal vasculitis for Beovu patients a number of which may lead to vision complications.  According to Novartis, the company “stands behind the safety and efficacy of Beovu. In addition to our own internal assessment, we have engaged an external safety review committee (SRC) to further evaluate these post-marketing cases. We will continue to share details as they become available.  The FDA is aware of our ongoing review and we’re in the process of informing other health authorities. Our clinical development and pharmacovigilance teams are working with healthcare professionals to quickly obtain and evaluate all available information in order to classify these events and identify potential risk factors.”

 

The New York Times has commented that around 46,000 injections of Beovu have been administered and the U.S. Food and Drug Administration are currently aware of the review. Beovu (brolucizumab or RTH258) is a humanized single-chain antibody fragment (scFv) and, according to Novartis, the drug is a small molecule (26 kDa) targeting all VEGF-A isoforms inhibit the activation of VEGF receptors through prevention of the ligand-receptor interaction. Clinical trials had previously reported that approx. 1,800 patients demonstrated non-inferiority for Beovu versus aflibercept in mean change in BCVA for 12 months.  According to studies, approximately 30% of patients treated with Beovu gained at least 15 letters.  In addition, Novartis reported that Beovu exhibited an overall safety profile comparable to aflibercept with the most common adverse events being blurred vision, cataract, conjunctival hemorrhage, vitreous floaters and eye pain (≥5% of patients).  The external safety review of the complication with vasculitis is awaiting their findings, in addition to a pending report from the FDA.

PrevPrevious
NextNext

You might also like

EURETINA Hamburg 2022 Keynote Speakers

Read More

EURETINA Educational Webinar: Diabetes and Vascular Diseases (23 Jun, 2022)

Read More

Apellis International: The Future of Geographic Atrophy: advancing diagnosis, treatment and management

Read More

Meet the Keynote Speakers

Keynote Speaker - Sobha Sivaprasad
Euretina Lecture with Sobha Sivaprasad
Opthalmologica Lecture with Enrico Borrelli
Ophthalmologica Lecture with Enrico Borrelli
Gisbert Richard Lecture with Catherine Creuzot-Garcher
Gisbert Richard Lecture with Catherine Creuzot-Garcher
Kreissig Award Lecture with Hiroko Terasaki
Kreissig Award Lecture with Hiroko Terasaki

Secretariat Address
European Society of Retina Specialists
Ground Floor, The Apex Building 
Blackthorn Road
Sandyford Business Park
Co Dublin, D18 H6K2

Phone:+353 1 2100092
Email: [email protected]

EURETINA 2022 Hamburg

Opportunities

Memberships

Forum

About

Privacy Policy

Newsletter Sign up

By clicking 'Subscribe', you agree to the terms of our Privacy Policy. 
 
 

Follow us

© EURETINA 2021 All rights reserved
  • Events
    • Future Meetings
    • Digital Events
    • EURETINA 2022 Hamburg
      • Browse Programme
      • Registration Information
      • Hotel Bookings
    • EURETINA 2021 Virtual
      • 2021 Virtual Sessions On-Demand (Members Only)
      • Programme
      • Satellite Symposia
      • Sponsors
  • Free Resources
    • Webinars
    • Podcasts
    • 2021 Virtual Session Abstracts
    • EURETINA Guidelines
    • EURETINA Brief
    • IME ePlatform
  • Membership
  • About
    • EURETINA Board
    • Subspecialty Sections
    • Bye-laws
  • Opportunities
    • Mentorship Programme 2022/23
    • RMCR grant programme
    • Observership Grant Programme
    • Women in Retina
    • YOURS
    • CME Credits
  • Member Login